Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 775 of 5804
-
New combo therapy shows promise for rare, aggressive skin cancer
Disease control OngoingAngiosarcoma is a rare and aggressive form of soft tissue sarcoma. Prior work demonstrates very poor outcomes, with most patients developing metastatic disease and less than 50% surviving greater than 5 years. In other soft tissue sarcomas, the use of radiotherapy and/or chemothe…
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Simple blood test aims to spot multiple cancers early
Diagnosis Recruiting nowTo acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negativ…
Sponsor: Helio Genomics • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
Blood plasma injection aims to wake up dormant ovaries in menopause
Disease control Recruiting nowAutologous PRP intra ovarian infusion may restore ovarian function, may promote folliculogenesis and may improve hormonal profile of women in menopause.
Phase: PHASE2, PHASE3 • Sponsor: Genesis Athens Clinic • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New pill shows promise for Hard-to-Treat lymphoma
Disease control OngoingThe purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.
Phase: PHASE1, PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo therapy aims to reignite immune attack on drug-resistant tumors
Disease control OngoingThis is a phase I/II study that will evaluate the safety and toxicity of this combinatorial approach. Eligible patients \>18 years of age with histologically proven metastatic NSCLC, melanoma, RCC, or HNSCC who have failed PD-1 / PD-L1 checkpoint blockade therapy will be enrolled…
Phase: PHASE1, PHASE2 • Sponsor: Megan Daly, MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could a tiny implant replace daily blood thinners for AF patients?
Disease control CompletedThe primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX Device is a reasonable alternative to oral anticoagulation following percutaneous catheter ablation for high risk patients with non-valvular atrial fibrillation.
Phase: NA • Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Jun 26, 2026 18:32 UTC
-
Could less radiation be just as effective for HPV throat cancer?
Disease control Recruiting nowThis research study is studying lowering the standard dose of radiation and chemotherapy after surgery, to minimize the side effects and improve the quality of life.
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Zinc pills tested as shield against toxic mine waste on navajo land
Disease control Recruiting nowThis is a study to assess the effect of dietary zinc supplementation to mitigate biomarkers of metal toxicity in exposed tribal populations.
Phase: PHASE2 • Sponsor: University of New Mexico • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
One-Shot knee treatment could ease arthritis pain for over a year
Symptom relief CompletedThis phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg loreciv…
Phase: PHASE3 • Sponsor: Biosplice Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
New drug combo shows promise for tough lung cancer
Disease control CompletedThis is a multi-center phase II clinical trial of atezolizumab in combination with bevacizumab as first line treatment for locally advanced or metastasic high-intermediate tumour mutation burden selected NSCLC patients. 102 patients will be enrolled in this trial to examine the e…
Phase: PHASE2 • Sponsor: Fundación GECP • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Cancer drug shows promise in keeping sarcoma in check
Disease control CompletedMulticenter double-blind placebo-controlled randomized Phase II study comparing regorafenib® to placebo, as maintenance therapy in metastatic soft-tissue non-adipocytic sarcomas experiencing stable disease or response after 6 cycles of doxorubicin-based chemotherapy as 1st line c…
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for brain tumor patients: targeted radiation shows promise
Disease control OngoingThis single arm, open-label study will evaluate the efficacy of Lutathera (177Lu-DOTATATE) administered intravenously every 8 weeks for a total of 4 doses in patients with progressive WHO I-III or residual high-risk Ga-DOTATATE PET-MRI positive meningioma. Ga-DOTATATE PET-MRI sca…
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo therapy aims to clear lung cancer before surgery
Disease control OngoingThis is an open-label, randomised, two-arm, phase II, multi-centre clinical trial. 90 patients will be enrolled in this trial to examine the pathological Complete Response defined as the absence of residual tumor in lung and lymph nodes comparing patients treated with chemo-immu…
Phase: PHASE2 • Sponsor: Fundación GECP • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Engineered T-Cells take on recurrent solid tumors in new trial
Disease control Recruiting nowThe study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
Phase: PHASE1, PHASE2 • Sponsor: Immatics US, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for rare cancers: Triple-Drug attack shows promise
Disease control Recruiting nowThis phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth o…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New combo therapy shows promise for tough lung cancer
Disease control CompletedDurvalumab is a drug that stimulates the immune system to fight lung cancer. Durvalumab is FDA approved to treat lung cancer. Stereotactic body radiation therapy (SBRT) is a newer radiation treatment that gives fewer, but higher doses of radiation than standard radiation. With S…
Phase: PHASE2 • Sponsor: Brown University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental spinal injection aims to keep kids with rare disease moving
Disease control CompletedThe main aim of the study is to determine if SHP611 given by injection into the spinal fluid that surrounds the brain and spinal cord (intrathecal; IT) prolongs the time for children with Metachromatic Leukodystrophy (MLD) to retain the ability to move from place to place. Other …
Phase: PHASE2 • Sponsor: Shire • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New blood test could spot cancer early – 6,000+ join study
Diagnosis Recruiting nowThis study explores the potential value of a new blood test approach for early detection of cancer.
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 09:10 UTC
-
New drug combo aims to shrink tough colorectal tumors before surgery
Disease control Recruiting nowColorectal cancer of Mismatch Repair-deficient (dMMR)/ Microsatellite Instability-high (MSI-H) accounts for approximately 15% of all colorectal cancer patients, with a higher proportion in right colon cancer. Previous studies have found that colon cancer patients with dMMR/MSI-H …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Sleep apnea treatment after stroke may save lives
Disease control OngoingThe purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2)…
Phase: NA • Sponsor: University of Michigan • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC